Thoma Bravo agreed to acquire Kneat, a provider of digital validation and compliance software for the life sciences sector, in an all-cash deal valuing the Limerick, Ireland-based company at approximately C$650 million ($466 million). The private equity firm will pay C$6.50 per share for the software provider, which serves highly regulated industries with its quality process automation platform that automates critical compliance procedures.

The offer represents a 40% premium to Kneat's unaffected share price. Kneat will be delisted from the Toronto Stock Exchange upon completion of the transaction. The deal, subject to shareholder and regulatory approval, is expected to close in the third quarter of 2026, giving regulators time to review the acquisition of this compliance-focused technology provider serving pharmaceutical and biotech companies globally.

The acquisition underscores private equity's continued interest in specialized software companies serving regulated industries. Kneat's platform helps life sciences companies navigate complex validation requirements, a growing concern as regulatory oversight increases globally. Thoma Bravo sees value in consolidating this niche market segment where compliance technology remains in high demand from pharmaceutical companies seeking to streamline their validation processes.